$SNDX News

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced

Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 Congress

Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical Oncology

Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Transplant In Acute Leukemia Patients, With Favorable Pharmacokinetic Profile Supporting Flexible Administration At ASCO 2026

Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute Leukemia

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

Syndax To Present Data Showing Favorable Post-Transplant Outcomes With Revumenib In Acute Leukemia And Highlight Ongoing Pivotal Trials At ASCO 2026

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $37

Syndax Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?

Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $37

Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...

Syndax Pharmaceuticals Q1 Earnings Call Highlights

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Stock Slides After Q1 Revenue Misses Street Forecasts Despite 224% Growth

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update